These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27620355)

  • 1. Harder-to-Treat Patients: Recognizing Them and Adapting Treatment Strategies.
    Miedema MD; Virani SS
    Am J Cardiol; 2016 Sep; 118(6 Suppl):13A-8A. PubMed ID: 27620355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-lowering agents.
    Ewang-Emukowhate M; Wierzbicki AS
    J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):401-11. PubMed ID: 23811423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to implement clinical guidelines to optimise familial hypercholesterolaemia diagnosis and treatment.
    Farnier M; Civeira F; Descamps O;
    Atheroscler Suppl; 2017 Apr; 26():25-35. PubMed ID: 28434482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing the high-risk patient: therapeutic approaches in 2002.
    Schuster H;
    Atheroscler Suppl; 2003 Mar; 4(1):15-20. PubMed ID: 12714033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Up to date lipid lowering treatment].
    Paragh G; Karádi I
    Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel pharmacotherapies of familial hyperlipidemia.
    Drakopoulou M; Toutouzas K; Stefanadis C
    Pharmacol Ther; 2013 Sep; 139(3):301-12. PubMed ID: 23639874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Is statin treatment for children safe and effective?].
    Marchetti F; Cannioto Z
    Recenti Prog Med; 2008 Dec; 99(12):599-601. PubMed ID: 19388217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing early cardiovascular death in patients with familial hypercholesterolemia.
    Repas TB; Tanner JR
    J Am Osteopath Assoc; 2014 Feb; 114(2):99-108. PubMed ID: 24481802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial hypercholesterolemia: current treatment and advances in management.
    Huijgen R; Vissers MN; Defesche JC; Lansberg PJ; Kastelein JJ; Hutten BA
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):567-81. PubMed ID: 18402545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing.
    McCrindle BW; Urbina EM; Dennison BA; Jacobson MS; Steinberger J; Rocchini AP; Hayman LL; Daniels SR; ; ;
    Circulation; 2007 Apr; 115(14):1948-67. PubMed ID: 17377073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterozygous familial hypercholesterolemia case study.
    Friedrich DA
    J Am Acad Nurse Pract; 2010 Oct; 22(10):523-6. PubMed ID: 21040085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.
    Pijlman AH; Huijgen R; Verhagen SN; Imholz BP; Liem AH; Kastelein JJ; Abbink EJ; Stalenhoef AF; Visseren FL
    Atherosclerosis; 2010 Mar; 209(1):189-94. PubMed ID: 19818960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
    Zhao S; Wang Y; Mu Y; Yu B; Ye P; Yan X; Li Z; Wei Y; Ambegaonakr BM; Hu D;
    Atherosclerosis; 2014 Aug; 235(2):463-9. PubMed ID: 24950001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre.
    Chan RH; Chan PH; Chan KK; Lam SC; Hai JJ; Wong MK; Tam FC; Lam L; Chan CW; Lam YM; Siu DC; Tse HF; Lee SW
    Hong Kong Med J; 2012 Oct; 18(5):395-406. PubMed ID: 23018067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction.
    Toth PP
    Am J Cardiol; 2016 Sep; 118(6 Suppl):19A-32A. PubMed ID: 27620356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia.
    van der Graaf A; Hutten BA; Kastelein JJ; Vissers MN
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):345-51. PubMed ID: 16716095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades.
    Elis A; Zhou R; Stein EA
    Am J Cardiol; 2011 Jul; 108(2):223-6. PubMed ID: 21545982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.